You are here: Industry Insights > myeloid leukemia

News List

Immunotherapy biotech HCW Biologics sets terms for $50 million IPO firstwordpharma
July 08, 2021
HCW Biologics announced terms for its IPO on Wednesday, saying it plans to raise $50 million by offering 5.6 million shares at a price range of $8 to $10, reported Renaissance Capital.
FDA approves new treatment for patients with acute myeloid leukemia worldpharmanews
November 24, 2018
The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75 yea
FDA approves new treatment for patients with acute myeloid leukemia worldpharmanews
November 24, 2018
The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75 yea
Targeted therapy for acute myeloid leukemia biospectrumasia
September 05, 2017
The Leukemia & Lymphoma Society (LLS) has played a role in the advancement of each of these therapies at some point along their development.
New England Journal of Medicine publishes long-term results of Gleevec® worldpharmanews
March 13, 2017
In 2001 the U.S. Food and Drug Administration granted priority review for imatinib mesylate, sold under the name Gleevec®*, as an oral therapy for patients with chronic myeloid leukemia, or CML.